Business Context and Reporting Period
This Form 8-K is a current report filed by Catalyst Biosciences, Inc. on January 17, 2018, regarding events that occurred on January 12, 2018. The filing addresses Item 5.02, covering the appointment of certain officers and compensatory arrangements. Note: The request metadata lists "Gyre Therapeutics, Inc.", but the filing text explicitly identifies the registrant as Catalyst Biosciences, Inc.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation and equity grants.
| Executive Officer | 2018 Base Salary | 2017 Performance Bonus | Stock Options Granted |
|---|---|---|---|
| Nassim Usman, Ph.D. (CEO) | $480,800 | $303,417 | 95,000 shares |
| Fletcher Payne (CFO) | $345,301 | $152,536 | 26,000 shares |
| Howard Levy, M.B.B.Ch., Ph.D. (CMO) | $397,838 | $175,744 | 33,000 shares |
Option Terms: Exercise price of $15.13 per share; vesting in equal monthly installments over four years starting January 12, 2018.
Material Changes and Board Actions
- Executive Compensation: The Compensation Committee approved 2018 base salaries and 2017 performance bonuses for the CEO, CFO, and CMO.
- Equity Grants: Stock options were granted to the three executive officers under the 2015 Stock Incentive Plan.
- Director Departure: In anticipation of Dr. Harold E. Selick's departure from the Board effective February 15, 2018, the Board approved:
- Accelerated vesting of his outstanding grant for 10,000 shares issued in July 2017.
- Extension of the option exercise period for all his grants until July 11, 2020.
Guidance, Outlook, and Risks
The filing text does not provide financial guidance, operational outlook, management commentary on business strategy, or specific risk factors. The document is limited to reporting specific compensation and governance events.
Investor Verification Checklist
- Verify the total dilution impact of the 154,000 new stock options granted to executives.
- Confirm the total cash outflow for the 2017 performance bonuses totaling approximately $631,697.
- Review the 2015 Stock Incentive Plan to ensure sufficient shares were available for these grants.
- Monitor the effective date of Dr. Selick's departure (February 15, 2018) and any subsequent Board composition changes.